cosibelimab
cosibelimab: developed by 1 company · 1 clinical trial tracked.
cosibelimab evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect cosibelimab to CKPT; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could cosibelimab → CKPT affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
locally advanced and metastatic cutaneous squamous cell carcinomaCutaneous Squamous Cell CarcinomaSkin Cancer
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Checkpoint Therapeutics, Inc. (CKPT) locally advanced and metastatic cutaneous squamous cell carc… | Phase 1 |
Clinical Trials (1)
A Phase IV Master Protocol of Cosibelimab in Special Populations With Advanced Cutaneous Squamous Cell Carcinoma (CosiMaster)
Primary endpoint: Best Overall Response Rate (BORR)
Interventionalopen80 targetStarted 2026-07Completion 2032-122 sites · United StatesDana-Farber Cancer Institute
Frequently asked questions
Who is developing cosibelimab?
cosibelimab is being developed by Checkpoint Therapeutics, Inc..
How many clinical trials involve cosibelimab?
BioSniper tracks 1 clinical trial involving cosibelimab.